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iDITORIAL COMMENT
ingle-Lead Ventricular
acing Is No Longer an
ption for Sick Sinus Syndrome*
enning Rud Andersen, MD, DMSC,
ens Cosedis Nielsen, MD, PHD
arhus, Denmark
n this issue of the Journal, Link et al. (1) report a study on
he occurrence of pacemaker syndrome in the Mode Selec-
ion (MOST) trial. The MOST trial is the largest random-
zed trial of pacing mode selection in patients with sick sinus
yndrome (SSS), including a total of 2,010 patients who all
eceived rate-adaptive atrioventricular synchronous dual-
hamber pacing (DDDR) pacemakers and were randomly
ssigned to dual-chamber or rate-adaptive inhibited single-
ead ventricular (VVIR) pacing mode (N  996) (2). The
resent study aimed to evaluate the incidence, predictors,
nd treatment of pacemaker syndrome in the 996 patients
reated with VVIR pacing.
See page 2066
Pacemaker syndrome occurred in 18.3% of the patients
reated with VVIR pacing. The strongest predictor of
acemaker syndrome was a higher percentage of paced
eats, and all significant predictors of pacemaker syndrome
ere parameters promoting or strongly associated with a
igher percentage of ventricular paced beats. Pacemaker
yndrome caused a marked decrease in quality of life, which
mproved significantly after reprogramming to DDDR pac-
ng mode. Therefore, the present study adds a strong
rgument to always select an atrial based pacing mode for
atients with SSS.
EFINING PACEMAKER SYNDROME
he definition of pacemaker syndrome has been variable,
ncluding several subjective symptoms as well as various
bjective findings (3,4). In the study by Link et al. (1),
acemaker syndrome was clearly defined as either “new or
orsened dyspnea, orthopnea, elevated jugular pressure,
ales, and edema with ventriculoatrial conduction during
entricular pacing” or “symptoms of dizziness, weakness,
resyncope, or syncope and a 20 mm Hg reduction of
ystolic blood pressure when the patient was ventricular
aced as compared with atrial pacing or sinus rhythm.” Both
efinitions include serious symptoms that had to occur
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.HFrom the Department of Cardiology, Skejby Hospital, Aarhus, Denmark.ogether with objective findings indicating an adverse he-
odynamic effect of VVIR pacing. It is likely that the use of
uch strict definitions of pacemaker syndrome is associated
ith a more correct estimate of this syndrome.
NCIDENCE OF PACEMAKER SYNDROME
lmost one-fifth of the patients treated with VVIR pacing
eveloped pacemaker syndrome in the MOST trial (1). This
ncidence is similar to the 26% found in the Pacemaker
election in the Elderly trial (5,6). In contrast, in the trial of
nhibited single-lead ventricular pacing (VVI) versus inhib-
ted single-lead atrial pacing (AAI), only 2% of patients had
acemaker syndrome that required a change in pacing mode
7), and in the large Canadian Trial Of Physiological Pacing
CTOPP), only 2.7% underwent pacing mode change
ecause of pacemaker syndrome (8). In the two latter
rials, hardware randomization was used, and the change
n pacing mode to atrial-based pacing required a reop-
ration with implantation of an atrial lead and a new
acemaker. Therefore, it is likely that the threshold for
iagnosing pacemaker syndrome was higher in these
rials. A new operation not only results in an additional
ospitalization and costs but also is associated with a risk of
nfection and other complications in each individual case.
Is 20% the correct incidence of pacemaker syndrome
ithin the first years after pacemaker implantation in
atients with SSS treated with VVIR pacing? In the study
y Link et al. (1), the pacemaker programming followed
sual recommendations in elderly patients with SSS, and in
ase of pacemaker syndrome, reprogramming of the pace-
aker to reduce ventricular pacing was attempted before a
hange in pacing mode was performed. However, the
nvestigators were not blinded with respect to the assigned
acing mode, and therefore an overreporting of pacemaker
yndrome cannot totally be discounted. Furthermore, a
lacebo effect may have contributed to the improved quality
f life after programming to atrial based pacing. However,
he finding of a 20% incidence probably represents the best
stimate of pacemaker syndrome in patients with SSS
reated with VVIR pacing.
ACING MODE IN PATIENTS WITH SSS
wo large randomized trials have tested VVIR pacing
ersus dual-chamber pacing in patients with SSS, the
OST trial (2) and the CTOPP trial (in which 42% of the
,568 patients had SSS) (8). In both these trials, the
ncidences of the secondary end point “atrial fibrillation”
AF) were significantly less in the groups assigned dual-
hamber pacing than in the VVIR groups. On the basis of
hese findings and because of the high—and not reliably
redictable—incidence of pacemaker syndrome (1), VVIR
acing should no longer be used as the primary pacing mode
n patients with SSS; DDDR pacing is a better choice.owever, in both the MOST trial and the CTOPP trial, no
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June 2, 2004:2072–4 Editorial Commentignificant differences were observed in the other end points,
hat is, mortality, cardiovascular deaths, heart failure (HF),
r thromboembolism, between VVIR and DDDR pacing
2,8) In contrast, in the first randomized trial on pacing
ode selection in SSS, single-lead atrial pacing was found
o reduce not only AF but also total and cardiovascular
ortality, HF, and thromboembolism as compared with
VI pacing (7,9). Recently, the first randomized compari-
on of rate-adaptive inhibited single-lead atrial pacing
AAIR) and DDDR pacing was published (10). In the
AIR group, no significant change was observed in left
hamber diameters or left ventricular fractional shortening,
hereas in the DDDR groups, left atrial diameter increased
ignificantly and left ventricular fractional shortening de-
reased in those patients who were paced most. These
ndings documents a detrimental effect of long-term single-
ite right ventricular pacing, so-called ventricular desyn-
hronization. Right ventricular pacing induces an abnormal
entricular activation and contraction, which in turn leads to
reduced ventricular function and left atrial dilatation.
trial fibrillation was significantly more common in the
DDR groups than in the AAIR group, indicating that
entricular desynchronization also promotes AF. The re-
ults of the AAIR versus DDDR trial are in accordance
ith the recent analysis from the MOST trial (11) and the
esults of the Dual Chamber and VVI Implantable Defi-
rillator trial (12) In both these trials, higher percentages of
entricular pacing were associated with excess HF, and in
he MOST trial, also with excess AF (11). Ventricular
esynchronization may also explain the relative modest
ifferences in outcomes found in the large randomized
omparisons of DDDR and VVIR pacing (CTOPP and
OST trials); the benefit of preserving atrioventricular
ynchrony was probably at least partly outweighed by the
etrimental effects of ventricular desynchronization during
DDR pacing.
At present time, we consider AAIR pacing as the optimal
acing mode in patients with SSS not accompanied by
trioventricular (AV) block, bundle branch block, or carotid
inus syndrome. However, AAIR pacing does not protect
he patients against high-degree AV block, which has been
ound to develop in 0.6% to 1.7% of the patients per year
13,14). Therefore, a larger randomized comparison be-
ween AAIR and DDDR pacing is necessary to definitively
nswer which pacing mode should be chosen for these
atients. The ongoing Danish Multicenter Randomized
tudy on AAI or DDD Pacing in Sick Sinus Syndrome trial
s expected to answer this question (15).
UTURE STUDIES
ewer than 20% of the patients referred for primary pace-
aker implantations are suitable for AAIR pacing (10), and
he large majority of pacemaker patients have to be pro-
ected against or treated for AV block. If it was technically
ossible to confer this protection against AV block withoutxposing the patients for the potential harmful effects of
entricular desynchronization, such a solution would be the
est also for patients who today are treated with an AAIR
acemaker.
For patients without manifest AV block, new pacemaker
lgorithms should be developed to reduce ventricular pacing
o a minimum and still protect the patients against AV
lock. Different AV hysteresis algorithms have already been
mplemented in newer pacemaker types; however, their
erformance in reducing ventricular pacing have only been
tudied sparsely and have not been impressive (16,17). To
educe ventricular stimulation to a minimum, it is necessary
o leave the fundamental principle in dual-chamber pacing,
hat every atrial event must always be followed by a
entricular event–sensed or paced. This would allow a real
ode-shift between AAIR and DDDR pacing modes (18).
For patients who need ventricular pacing most of the
ime, alternative strategies of pacing the ventricle(s) should
e studied. Theoretically, selection of other ventricular
acing sites as well as multiple ventricular pacing sites might
ause less ventricular desynchronization and thereby a better
atient outcome.
In both cases, such trials on pacing mode selection should
e powered to study not only the achieved percentages of
entricular paced beats, but also what is important for the
atients: the clinical outcome–HF, AF, and mortality.
ased on our present knowledge, VVIR pacing should no
onger be considered an option for patients with SSS.
eprint requests and correspondence: Dr. Henning Rud
ndersen, Department of Cardiology B, Skejby Hospital,
rendstrupgaardsvej, DK-8200 Aarhus N, Denmark. E-mail:
enning.rud.andersen@dadlnet.dk.
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